Estimation of induction and maintenance costs of Infliximab, Adalimumab and Cer-tolizumab Pegol in managing Crohnʼs DiseaseBrian G. Feagan, Martin C. Brown, Joaquín Hinojosa et al.|Inflammatory Bowel Diseases|2008Cited by 0